The materials you are responsible for are listed below. I would, of course, encourage you to browse through the other topics under Drug Therapies, including the several new drug approvals in the past 5 years (several new formulations of levodopa and amantadine, as well as, more importantly, 2 new first-in-class drugs: droxidopa and pimavanserin, for orthostatic hypotension and psychosis associated with Parkinson’s, respectively).
Physiological Basis of Parkinson’s
|What is dopamine and what does it have to do with Parkinson’s disease?|
|Where does dopamine come from?|
|What happens to dopamine after it is made?|
|Why do the dopamine producing cells die?|
|Is Parkinson’s disease genetic?|
|Intro to levodopa|
|Why must patients take levodopa so frequently?|
|What are the major side effects of levodopa?|
|Intro to MAO-B inhibitors|
|Intro to dopamine agonists|
We will also be doing an in-class exercise on optimizing levodopa dosing, using information from the Advanced Levodopa Pharmacokinetics page and LevodopaLevel.com.